Karakatsanis, S.J. Bouzani, M. Symeonidis, A. Angelopoulou, M.K. Papageorgiou, S.G. Michail, M. Gainaru, G. Kourti, G. sachanas, S. Kalpadakis, C. Katodritou, E. Leonidopoulou, T. Kotsianidis, I. Hatzimichael, E. Kotsopoulou, M. Dimou, M. Variamis, E. Boutsis, D. Kanellias, N. Dimopoulou, M.N. Michali, E. Karianakis, G. Tsirkinidis, P. Vadikolia, C. Poziopoulos, C. Pigaditou, A. Vrakidou, E. Economopoulos, T. Kyriazopoulou, L. Siakantaris, M.P. Kyrtsonis, M.-C. Anargyrou, K. Papaioannou, M. Hatjiharissi, E. Vervessou, E. Tsirogianni, M. Palassopoulou, M. Stefanoudaki, E. Zikos, P. Tsirigotis, P. Tsourouflis, G. Assimakopoulou, T. Verrou, E. Papadaki, H. Lampropoulou, P. Dimopoulos, M.-A. Pappa, V. Konstantopoulos, K. Karmiris, T. Roussou, P. Panayiotidis, P. Pangalis, G.A. Vassilakopoulos, T.P., Real-life Experience With Rituximab-CHOP Every 21 or 14 Days in Primary Mediastinal Large B-cell Lymphoma, In vivo (Athens, Greece), (36), 1302-1315, 2022, International Institute of Anticancer Research,